The Saul Priceman Laboratory

Saul Priceman, Ph.D., is assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratory. Priceman is a principal investigator and provides scientific oversight on solid tumor immunotherapy programs focused on the development of CAR-engineered T cells and rational combination approaches for prostate cancer, breast cancer brain metastasis, ovarian cancer, pancreatic cancer and other solid tumor types. The lab has primarily been focused on targeting prostate, breast, ovarian and pancreatic cancers.

The Barthel Laboratory

The Barthel Laboratory studies the role of telomere dysfunction in brain cancer (glioma) development and evolution. They are a part of the Cancer and Cell Biology Division at the Translational Genomics Research Institute (TGen) and the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research Institute (BRI) at City of Hope.

Sarah Shuck, Ph.D.

Dr. Sarah Shuck is an analytical chemist and assistant research professor at City of Hope. Her work is focused on analyzing components that are produced at the very earliest stages of type 1 diabetes and diabetic kidney disease, to try and identify the people who are most vulnerable.

Tanya Dorff, M.D.

Dr. Tanya Dorff is an associate professor in the Department of Medical Oncology & Therapeutics Research and serves as section chief of the Genitourinary Disease Program at City of Hope. She is an internationally recognized leader in prostate cancer, and is renowned for her work in other genitourinary tumor types, including kidney, bladder and penile cancer.

Zijie Sun, M.D., Ph.D.

Dr. Zijie (ZJ) Sun is a professor in the Department of Cancer Biology and the founding director of the prostate cancer research program in the Beckman Research Institute and the Comprehensive Cancer Center. Dr. Sun’s research interest focuses on the molecular mechanisms underlying transcriptional control and cell signaling in development and tumorigenesis.

An Liu, Ph.D.

Dr. An Liu is a clinical professor in the Department of Radiation Oncology as well as a clinical professor in and director of the Division of Radiation Physics at City of Hope.

David Engelthaler, Ph.D.

Dr. David Engelthaler is the Co-Director and Associate Professor of Pathogen Genomics Division at TGen North. TGen North focuses on pathogen genomics with a specific mission to advance clinical medicine, public health and biodefense. Dave is also the Executive Director of the Southwest One Health Collaborative, Director of the TGen North Clinical Laboratory and Co-Director of the AZ COVID-19 Genomics Union.

Stephen Gruber, M.D., Ph.D., M.P.H.

An internationally recognized cancer geneticist and oncologist, Dr. Stephen Gruber is a physician-scientist who focuses his clinical practice and research program on precision medicine and the genomics of cancer in order to improve treatment and care for cancer patients and their families. Dr. Gruber is an expert in Lynch syndrome and hereditary susceptibility to colorectal cancer.

Jeremy Stark, Ph.D.

The long-term goal of Dr. Stark’s laboratory research program is to understand the factors and pathways that influence mammalian genome stability. Such studies provide important insights into the etiology of cancer, as well as the mechanisms of cancer cell resistance to clastogenic therapeutics.